tiprankstipranks
Trending News
More News >
UG Healthcare Corp. Ltd. (SG:8K7)
:8K7
Singapore Market
Advertisement

UG Healthcare Corp. Ltd. (8K7) AI Stock Analysis

Compare
0 Followers

Top Page

SG:8K7

UG Healthcare Corp. Ltd.

(SGX:8K7)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 4o)
Rating:48Neutral
Price Target:
S$0.10
▼(-4.00% Downside)
The overall stock score is primarily influenced by financial performance challenges, including profitability and cash flow issues, despite strong revenue growth. Technical indicators suggest a neutral to slightly bearish trend, while valuation concerns arise from negative earnings and lack of dividend yield.
Positive Factors
Revenue Growth
Strong revenue growth indicates robust demand for UG Healthcare's products, enhancing its market position and potential for future expansion.
Diversified Revenue Model
A diversified revenue model reduces dependency on single income streams, providing stability and resilience against market fluctuations.
Moderate Debt Level
Moderate leverage provides financial stability, allowing UG Healthcare to invest in growth opportunities without excessive risk.
Negative Factors
Profitability Challenges
Negative profit margins suggest inefficiencies or high costs, which could impede long-term financial health if not addressed.
Cash Flow Issues
Declining cash flow generation limits the company's ability to fund operations and invest in growth, posing a risk to sustainability.
Negative Return on Equity
Negative ROE indicates that the company is not generating sufficient returns on shareholder investments, impacting investor confidence.

UG Healthcare Corp. Ltd. (8K7) vs. iShares MSCI Singapore ETF (EWS)

UG Healthcare Corp. Ltd. Business Overview & Revenue Model

Company DescriptionUG Healthcare Corp. Ltd. (8K7) is a prominent player in the healthcare sector, primarily focused on the manufacturing and distribution of medical gloves and other healthcare-related products. The company operates in various markets, providing essential products to hospitals, clinics, and healthcare providers worldwide. With a commitment to quality and innovation, UG Healthcare has established a strong reputation for its nitrile and latex gloves, catering to both the medical and industrial sectors.
How the Company Makes MoneyUG Healthcare Corp. Ltd. generates revenue through the sale of its core products, primarily medical gloves, which are sold to healthcare facilities, distributors, and retailers globally. The company benefits from a diversified revenue model that includes both direct sales and partnerships with key distributors in various regions. Additionally, UG Healthcare leverages economies of scale in its manufacturing processes, allowing for competitive pricing and increased profit margins. The company's focus on quality assurance and compliance with international standards further enhances its market position, attracting long-term contracts and repeat business from clients. Significant partnerships with healthcare institutions and suppliers also contribute to its earnings, providing a steady stream of revenue.

UG Healthcare Corp. Ltd. Financial Statement Overview

Summary
UG Healthcare Corp. Ltd. shows strong revenue growth but faces profitability and cash flow challenges. The company has a moderate debt level, providing some financial stability, but negative returns on equity and cash flow issues are concerning.
Income Statement
45
Neutral
UG Healthcare Corp. Ltd. has experienced significant revenue growth of 51.77% in the latest year, indicating strong sales performance. However, the company is facing profitability challenges, with a negative net profit margin of -2.63% and an EBIT margin of -0.87%. This suggests that despite increasing revenues, the company is struggling to convert sales into profits, potentially due to high operating costs or other inefficiencies.
Balance Sheet
60
Neutral
The company's debt-to-equity ratio of 0.30 indicates a moderate level of leverage, which is relatively stable compared to previous years. However, the return on equity is negative at -2.39%, reflecting the company's inability to generate positive returns for shareholders. The equity ratio stands at 68.33%, suggesting a strong equity base relative to total assets, which provides some financial stability.
Cash Flow
40
Negative
UG Healthcare Corp. Ltd. has a negative free cash flow growth rate of -78.07%, indicating a significant decline in cash generation. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. However, the free cash flow to net income ratio of 1.70 suggests that the company is generating more free cash flow relative to its net income, which could be a positive sign if sustained.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue94.93M144.07M115.20M101.13M232.60M338.40M
Gross Profit3.43M34.74M25.87M1.45M84.39M196.16M
EBITDA-21.20M2.47M-3.94M-23.97M53.37M163.04M
Net Income-20.93M-3.79M-6.06M-20.73M36.80M118.77M
Balance Sheet
Total Assets215.39M232.35M226.45M230.00M288.04M268.29M
Cash, Cash Equivalents and Short-Term Investments45.13M23.29M28.00M61.74M100.22M68.44M
Total Debt28.46M47.36M43.72M31.13M17.98M16.74M
Total Liabilities44.08M76.03M65.17M48.81M52.98M73.53M
Stockholders Equity171.94M158.73M163.39M180.84M228.90M190.64M
Cash Flow
Free Cash Flow-36.98M-8.11M-20.71M-47.17M31.63M61.47M
Operating Cash Flow-34.35M-4.78M-18.16M-39.14M53.95M81.16M
Investing Cash Flow-2.63M-3.21M-22.73M-8.03M-21.19M-18.89M
Financing Cash Flow4.62M3.24M8.36M8.70M-973.00K-3.14M

UG Healthcare Corp. Ltd. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.10
Price Trends
50DMA
0.10
Negative
100DMA
0.10
Negative
200DMA
0.11
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
47.34
Neutral
STOCH
161.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8K7, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.34 is Neutral, neither overbought nor oversold. The STOCH value of 161.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:8K7.

UG Healthcare Corp. Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
73
Outperform
S$1.36B18.4814.10%9.58%4.74%-17.18%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
S$60.51M-2.33%25.06%37.11%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SG:8K7
UG Healthcare Corp. Ltd.
0.10
-0.02
-16.38%
SG:AP4
Riverstone Holdings
0.82
-0.15
-15.46%
SG:1J5
Hyphens Pharma International Ltd.
0.35
0.07
27.27%
SG:546
Medtecs International Corporation Ltd.
0.12
-0.01
-7.69%
SG:BFK
Pharmesis International Ltd.
0.40
-0.26
-39.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 29, 2025